News
Alpha-1 Foundation announces Million Dollar Match program made possible by a grant from Talecris Biotherapeutics
RESEARCH TRIANGLE PARK, N.C. and MIAMI, FL — The Alpha-1 Foundation announced today it will receive up to $1 million in grant matching funds from Talecris Biotherapeutics, Inc. to support research into Alpha-1 Antitrypsin Deficiency, a genetic condition in which low levels of the essential blood protein alpha1-proteinase inhibitor, can cause emphysema.
The Talecris grant matches every dollar the Foundation raises in donations for research, up to one million dollars. Talecris developed and manufactures Prolastin® (Alpha1-Proteinase Inhibitor [Human]), a leading treatment for alpha1-antitrypsin deficiency. The condition is the most prevalent, potentially fatal hereditary disease of Caucasians, having a greater prevalence in adults than cystic fibrosis.
“Talecris’ generous and long-standing support has helped to advance the mission of the Alpha-1 Foundation for many years,” said John Walsh, President and CEO of the Foundation. “With their latest grant, every dollar donated for research—up to a million dollars—will be doubled this year.”
